• 11/17/2016
      Sughrue has once again made it among the elite patent litigation firms to make the "Top Tier" rank in the annual U.S. News and World Report Best Lawyers rankings. Sughrue was recognized in the Best Law Firm top tier rankings in the areas of Intellectual Property Litigation and Patent Litigation. Sughrue has obtained the coveted “Tier 1” ranking for four consecutive years.

      Best Lawyers is the oldest and most prestigious peer-review publication in the legal profession. Attorneys are peer-nominated and evaluated by a panel of attorneys within their practice area. Nominations are put through a rigorous evaluation process which includes client feedback regarding responsiveness, understanding of business and its needs, cost effectiveness and civility.

      Sughrue Mion, based in Washington D.C., is a leading global intellectual property firm, counseling clients as they navigate the complexities of patent and trademark law. Sughrue’s practice is focused solely on intellectual property law, including counseling, prosecution, licensing, litigation, portfolio management and enforcement. Sughrue brings unmatched experience in patent interference proceedings and Post Grant Review, including ex parte and inter partes reexamination proceedings. In addition to their legal expertise, Sughrue’s attorneys have technical and scientific backgrounds ranging from electrical and computer technology to biotechnology and pharmaceuticals, allowing for a true understanding of their clients’ business challenges and goals.
    • 11/2/2016

      On November 8, 2016, John Rabena will discuss “the recent key developments at the International Trade Commission and companies' options after an exclusion order has been issued” at the Service Center of Shanghai Municipal Commission of Commerce, Shanghai China.

      The Service Center of Shanghai Municipal Commission of Commerce is responsible for, among other things, promoting the export of technology, software, and products with independent IPR; facilitating companies' business expansion, diversifying markets, and helping local famous brands to expand in domestic and international markets.

      For more information, please click here.

    • 10/26/2016
      John Bird, a partner in the Washington D.C. office of Sughrue Mion, PLLC will participate in a upcoming webcast entitled, "PTAB Patent Proceedings: Best Practices and Strategies."
    • 9/13/2016
      Sughrue attorneys Michael Dzwonczyk, Chid Iyer and Azy Kokabi along with several codefendants in Eli Lilly and Company et al. v. Accord Healthcare, et al. (S.D. In.), successfully challenged every claim of two Orange Book listed patents in an inter partes review proceeding (IPR) at the U.S. Patent Office. On September 12, 2016, The PTAB found that claims 1-27 of Daiichi Sankyo's and Ube Industries' U.S. Patent No. 8,404,703 and claims 1-26 of U.S. Patent No. 8,569,325 were unpatentable based on prior art that showed every limitation of the challenged claims would have been obvious. Rejecting patent owners' claims that administering a combination of prasugrel and aspirin yielded surprising and unexpected results, the PTAB found that the difference in net clinical benefit between the claims and those of the prior art was merely one of degree, not one in kind.
    More News